Panaxia Labs Israel Ltd
Panaxia Pharmaceutical Industries Ltd provides pharmaceutical solutions for patients and physicians. The company offers pharma-grade smokeless cannabis products, such as oral and sublingual tablets, medical oils, concentrations, pastilles, suppositories, topical creams, pain relief creams, and pain relief patches. Panaxia Pharmaceutical Industries Ltd has strategic partnerships with Ultra Health,… Read more
Panaxia Labs Israel Ltd (HROD) - Total Liabilities
Latest total liabilities as of June 2019: ILA31.85 Million ILA
Based on the latest financial reports, Panaxia Labs Israel Ltd (HROD) has total liabilities worth ILA31.85 Million ILA as of June 2019.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Panaxia Labs Israel Ltd - Total Liabilities Trend (2015–2018)
This chart illustrates how Panaxia Labs Israel Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Panaxia Labs Israel Ltd Competitors by Total Liabilities
The table below lists competitors of Panaxia Labs Israel Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chrometco Ltd
JSE:CMO
|
South Africa | ZAC1.35 Billion |
|
Kalium Lakes Ltd
AU:KLL
|
Australia | AU$308.00K |
|
TRIPADVISOR
BE:T6A
|
Germany | €1.79 Billion |
|
TRACON Pharmaceuticals Inc
OTCQB:TCON
|
USA | $10.49 Million |
|
VILKYSKIU PIENINE (UDW.SG)
STU:UDW
|
Germany | €54.09 Million |
|
Centrais Electricas Brasileiras S.A.- Eletrobr?!s American Depositary Shares (Each representing one Preferred Share)
NYSE:EBRB
|
USA | $107.64 Billion |
|
FRBP
PINK:FRBP
|
USA | $2.46 Billion |
Liability Composition Analysis (2015–2018)
This chart breaks down Panaxia Labs Israel Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Panaxia Labs Israel Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Panaxia Labs Israel Ltd (2015–2018)
The table below shows the annual total liabilities of Panaxia Labs Israel Ltd from 2015 to 2018.
| Year | Total Liabilities | Change |
|---|---|---|
| 2018-12-31 | ILA6.42 Million | -64.10% |
| 2017-12-31 | ILA17.89 Million | +7.31% |
| 2016-12-31 | ILA16.67 Million | -1.49% |
| 2015-12-31 | ILA16.92 Million | -- |